Article Text

Download PDFPDF
Blood group B is associated with azathioprine-induced acute pancreatitis in patients with IBD
  1. Niels Teich1,
  2. Bernd Bokemeyer2,
  3. Wolfgang Mohl3,
  4. Jens Walldorf4,
  5. Tony Bruns5,
  6. Carsten Schmidt5,
  7. Andreas Stallmach5
  8. on behalf of the German IBD Study Group
  1. 1 Internistische Gemeinschaftspraxis, Leipzig, Germany
  2. 2 Gastroenterologische Gemeinschaftspraxis, Minden, Germany
  3. 3 Gemeinschaftspraxis—Endoskopiezentrum, Saarbrücken, Germany
  4. 4 Universitätsklinikum Halle, Universitätsklinik und Poliklinik für Innere Medizin I, Halle, Germany
  5. 5 Universitätsklinikum Jena, Klinik für Innere Medizin IV, Jena, Germany
  1. Correspondence to Dr Niels Teich, Internistische Gemeinschaftspraxis für Verdauungs-und Stoffwechselkrankheiten, Nordstr. 21, Leipzig D-04105, Germany; teich{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

In a recently published study of asymptomatic volunteers from a population-based study (n=3966) and healthy blood donors (n=1444), genetic polymorphisms that determine the fucosyltransferase-2 non-secretor status and the ABO blood type B were significantly associated with increased serum lipase activities.1 Furthermore, the study was the first one to identify the inherited Lewis and ABO blood group systems as relevant factors for the development of pancreatitis, that is, blood group B carriers displayed 1.69-fold odds of developing chronic pancreatitis.1 Little is known about the pathogenesis of azathioprine-induced acute pancreatitis (AIAP) in patients with inflammatory bowel diseases (IBDs). In a first prospective multicentre study on the incidence of AIAP in patients with thiopurine-naive IBD, we were able to identify smoking at the time of azathioprine induction as the strongest and dose-dependent risk factor.2 Stimulated by the findings of Weiss et al,1 we have this time investigated whether patients with IBD who …

View Full Text


  • Collaborators The following collaborators are members of the German IBD Study Group. They provided and cared for five or more study patients:

  • Lars Helmstädter, Ingolf Schiefke, Tobias Klugmann, Oliver Bachmann, Manfred von der Ohe, Gisela Felten, Burkhard Bündgens, Thomas Klag, Dominik Bettenworth, Donata Lissner, Renate Schmelz, Jürgen Büning, Britta Siegmund, Christian Maaser and Martin Schmidt-Lauber.

  • Contributors Conception or design of the work: NT and AS. Acquisition of data: NT, BB, WM, JW, CS and AS. Analysis of data: NT, TB, CS, and AS. Interpretation of data, drafting the work or revising it critically for important intellectual content and final approval of the version published: all authors. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

  • Competing interests None.

  • Ethics approval The protocol has been approved by the Institutional Review Board at Jena University, Germany.

  • Provenance and peer review Not commissioned; internally peer reviewed.